AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03045627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AraC
Description: ARA-C subcutaneously in a 12-hour infusion on days 1 through 14
Study NCT03045627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aclarubicin
Description: Aclarubicin(Acla) 5～7mg/m2/d，intravenously on days 1 through 8
Study NCT03045627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-G-CSF
Description: PEG-G-CSF 6mg subcutaneously on days 0.
Study NCT03045627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: G-CSF 200 μg·m-2·d-1, subcutaneously on days 0 through 14.
Study NCT05636891 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Stimus
Description: * NNG-DEPO (Darbepoetin alfa 10 mcg/0.4 mL, 20 mcg/0.5 mL, 40 mcg/0.4 mL, 60 mcg/0.3 mL) is available as a prefilled syringe in a sterile, colorless, glass tube.~* Aranesp® (Darbepoetin alfa 10 mcg/ 0.4 mL, 20 mcg/ 0.5 mL, 40 mcg/ 0.4 mL, 60 mcg/ 0.3 mL) is manufactured by Amgen, as a pre-filled syringe in a sterile, glass tube, colourless.~Storage: 2-8ºC, not frozen. The process of transporting and storing the drug must ensure the temperature in the range of 2-8ºC.~NNG-DEPO/Aranesp is administered subcutaneously (or intravenously for patients with PK-PD in the previous IV group), at a dose of 0.75 g/kg initially, every 2 weeks at the second visit.~IPs will be prepared according to standard procedure (SOP). Dosage adjustment guideline:~Patients will have hemoglobin levels monitored every 2 weeks. The investigators will evaluate and adjust the dose of Darbepoetin alfa to maintain the Hb levels within the target range (10 - 12 g/dL)
Study NCT05636891 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stimus
Description: * NNG-DEPO (Darbepoetin alfa 10 mcg/0.4 mL, 20 mcg/0.5 mL, 40 mcg/0.4 mL, 60 mcg/0.3 mL) is available as a prefilled syringe in a sterile, colorless, glass tube.~* Aranesp® (Darbepoetin alfa 10 mcg/ 0.4 mL, 20 mcg/ 0.5 mL, 40 mcg/ 0.4 mL, 60 mcg/ 0.3 mL) is manufactured by Amgen, as a pre-filled syringe in a sterile, glass tube, colourless.~Storage: 2-8ºC, not frozen. The process of transporting and storing the drug must ensure the temperature in the range of 2-8ºC.~NNG-DEPO/Aranesp is administered subcutaneously (or intravenously for patients with PK-PD in the previous IV group), at a dose of 0.75 g/kg initially, every 2 weeks at the second visit.~IPs will be prepared according to standard procedure (SOP). Dosage adjustment guideline:~Patients will have hemoglobin levels monitored every 2 weeks. The investigators will evaluate and adjust the dose of Darbepoetin alfa to maintain the Hb levels within the target range (10 - 12 g/dL)
Study NCT05578469 — intervention group
Intervention type: PROCEDURE
Intervention: surgical treatment of Marfan Syndrome with subluxation lens
Description: different surgical treatment of Marfan Syndrome with subluxation lens
Study NCT02999698 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Observational
Study NCT03562845 — intervention group
Intervention type: OTHER
Intervention: NA-Observational only
Description: NA-Observational only
Study NCT05476133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Executive functions training-elementary and Promoting executive function in in the classroom
Description: evidence based practice that target executive function skills in early elementary years.
Study NCT00850447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy
Description: Cognitive Remediation Therapy (CRT) is a standardized intervention that involves performing cognitive exercises to improve attention, processing speed, and memory through practice. Participants will have one 60-minute CRT session each week for ten weeks. The CRT to be used in the proposed study is CogPack (version 6.0 Marker Software, Mannheim Germany). CogPack demonstrates flexibility in terms of developing a targeted intervention plan based on the levels of baseline cognitive impairment. There are approximately 6 different exercises presented in each training session, with the starting level of difficulty individualized on the basis of baseline neuropsychological performance.
Study NCT00850447 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Videogame
Description: Participants will play the videogame Tetris once each week for 30 minutes. Tetris is a video puzzle game that involves manipulating falling shapes. The object of the game is to manipulate these shapes, by moving them sideways or rotating them, to create a horizontal line of blocks without gaps. As the game progresses, the shapes fall faster.
Study NCT02002858 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational-Support Psychotherapy
Description: Educational-based psychotherapy and standard smoking cessation treatment program
Study NCT04659668 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MMG-23-04-2019
Description: The dermal filler MMG-23-04-2019 is applied to the female intimate area (intramucosal administration) of vaginal vestibule, vaginal walls, clitoris, G spot.
Study NCT03316157 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ProSure
Description: Patients will take 2x 220mL nutritional supplements per day for 8 weeks and be given dietary advice to optimise their nutrition
Study NCT03316157 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: Patients will receive an individualised exercise regimen consisting of 60 minutes aerobic and 3x resistance elements per week
Study NCT03999073 — intervention group
Intervention type: OTHER
Intervention: Ultrasound measurement
Description: Ultrasound measurement
Study NCT02389738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: Regadenoson administration on post-op day 2 after temozolomide administration. Temozolomide plasma and dialysate concentrations will be obtained over 18 hours post temozolomde administration.
Study NCT02389738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide administration on post-op day 1 and 2. Temozolomide plasma and dialysate concentrations will be obtained over 18 hours post temozolomde administration.
Study NCT02389738 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microdialysis catheter
Description: Microdialysis catheter placement post surgical resection and removed at the bedside after completion of obtaining all dialysate collections.
Study NCT03163329 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAVR
Description: Transcatheter Aortic Valve Replacement
Study NCT03163329 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SAVR
Description: Surgical Aortic Valve Replacement
Study NCT03563560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvocidib
Description: ACM regimen:30 mg/60 mg, 30-minute intravenous (IV) infusion, followed 4-hour IV infusion from Day 1 to Day 3 A+7+3 regimen: recommended dose (RD), 30-minute IV infusion, followed 4-hour IV infusion from Day 1 to Day 3
Study NCT03563560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 300 or 667 mg/m2/day, 72-hour continuous IV infusion starting on Day 6 (ACM regimen)
Study NCT02342912 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Media Treatments
Description: Each of the three intervention groups offers information that has been shown to be important for college students to have a healthy body weight. All three groups provide information on topics that we know are related to having a healthy body weight, like managing stress, keeping track of how you spend your time, and increasing self-awareness of certain health behaviors. Two of the three programs are focused on weight loss for a healthy body. The third group focuses on having a healthy mind, body and having energy during college.
Study NCT03563560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: 14 or 40 mg/m2/day, IV infusion over 1 hour to 2 hours at 12 hours after the end of DSP-AraC administration (acceptable range + 3 hours)
Study NCT03563560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 100 mg/m2/day, continuous IV infusion for 7 days from Day 5 to Day 11 (A+7+3 regimen)
Study NCT01620827 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hospital Landline Phone Calls
Description: Follow-up phone calls are made from the hospital landline phones in a research office
Study NCT04427111 — intervention group
Intervention type: DEVICE
Intervention: Non-titratable-customized mandibular advancement device
Description: The most comfortable protruded mandibular position situated between 60-75% of MMPV was determined according to patient response with 6mm of the vertical interocclusal dimension between maxillary and mandibular central incisors and registered. The upper and lower acrylic resin splints were secured to each other in the posterior region with auto polymerizing acrylic resin and NTC-MADs were obtained. The patients were instructed to wear their non-titratable-customized mandibular advancement device every night.
Study NCT01620827 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Private Cell Phone Calls
Description: Follow-up phone calls are made from the private cell phones of research assistants
Study NCT02249481 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor Canal catheter delivering 0.0625% L- Bupivacaine
Description: Adductor canal catheter: Blockade at mid-thigh. Identify sartorius at mid thigh - find point where the femoral artery begins to descend from sartorius. In plane technique, hydro-dissect space between sartorius and femoral artery. Catheter threaded and 2-4cm left in situ (bevel orientated cephalad). Bolus 20 mls via needle and 5 mls via catheter to confirm spread under ultrasound guidance. Glue/Lockit dressing.
Study NCT02249481 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral nerve catheter delivering 0.0625% L- Bupivacaine
Description: Femoral nerve catheter: Blockade at level of Femoral crease. Identify femoral nerve. In plane lateral approach. Bolus 20 mls via needle. Catheter threaded and 2-4cm left in situ (bevel orientated cephalad).and 5 mls injected via catheter to confirm spread under ultrasound guidance. Glue/Lockit dressing.
Study NCT00915850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCF
Description: docetaxel, Cisplatin and 5-FU
Study NCT04574245 — intervention group
Intervention type: PROCEDURE
Intervention: Gastrectomy; Hepatectomy
Study NCT03614832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg
Description: half-dose ticagrelor treatment (90 mg loading dose, then 90 mg once daily) for 1 week.
Study NCT03614832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 150 mg
Description: double standard-dose clopidogrel treatment (150 mg loading dose, then 150 mg once daily) for 1 week.
Study NCT03833011 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulation
Description: Osteopathic manipulation
Study NCT02028910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: The treatment is administered orally in a single dose of 2.5 ml = 2 mg per 5 kg weight of the child, not to exceed the maximum dose of 10mg. A second dose, the same dose is given back if the child vomits within 15 minutes after the first administration.~The bottle contains at least 2 doses of up to 10 mg for a second dose can be given back in case of vomiting within 15 minutes after the first dose in children weighing more than 25 kg.~The dosage should be adjusted according to the weight of the child
Study NCT02028910 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron
Description: The treatment is administered orally in a single dose of 2.5 ml = 2 mg per 5 kg weight of the child, not to exceed the maximum dose of 10mg. A second dose, the same dose is given back if the child vomits within 15 minutes after the first administration.~The bottle contains at least 2 doses of up to 10 mg for a second dose can be given back in case of vomiting within 15 minutes after the first dose in children weighing more than 25 kg.~The dosage should be adjusted according to the weight of the child
Study NCT03427229 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Single-infusion FMT
Description: Patients will receive a single fecal infusion by colonoscopy
Study NCT03427229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin (before randomization)
Description: Vancomycin is administered in all patients for 3 days before randomization. Then vancomycin is stopped and patients are randomized to single-infusion FMT or multiple-infusion FMT.
Study NCT03427229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin (before randomization)
Description: Vancomycin is administered in all patients for 3 days before randomization. Then vancomycin is stopped and patients are randomized to single-infusion FMT or multiple-infusion FMT.
Study NCT03427229 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: multiple-infusion FMT
Description: Patients will receive multiple fecal infusions by colonoscopy
Study NCT01452672 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: RT 40 Gy in 15 fractions
Study NCT01452672 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Irradiation of the chest-wall and supraclavicular fossa
Description: RT 40Gy in 15 fractions
Study NCT01884974 — intervention group
Intervention type: OTHER
Intervention: myeloproliferative disease
Description: Echocardiogram, demographic data, St George respiratory questioner
Study NCT04438811 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: delivery of the spinal anesthetic by a trained medical officer
Description: The delivery of spinal anesthesia by the trained medical officers in 3 rural Indian hospitals will be compared to those delivered by consultant anesthetists in the same hospitals in a non-inferiority analysis.
Study NCT04438811 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: delivery of spinal anesthetic by a consultant anesthetist
Description: The delivery of spinal anesthesia by the trained medical officers in 3 rural Indian hospitals will be compared to those delivered by consultant anesthetists in the same hospitals in a non-inferiority analysis.
Study NCT04034238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMB-100
Description: Arms 1 and 2: Administered intravenous (IV) as an approximate 30-minute infusion of each 21-day cycle on days 4, 6 and 8 until disease progression, intolerance or withdrawal from study.
Study NCT04034238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Arms 1 and 2: Administered orally twice daily on days 1-10 of each cycle until disease progression, intolerance or withdrawal from study.
Study NCT04034238 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mesothelin Expression
Description: Test for mesothelin expression in tumor tissues for study eligibility
Study NCT04729543 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adoptive therapy with autologous MC2 TCR T cells
Description: Adoptive therapy with autologous MC2 TCR T cells combined with AZA/VP
Study NCT03992638 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: leucocyte and platelet-rich fibrin (L-PRF) in combination with CAF
Description: Completing root coverage by coronally advanced flap technique in combination with L-PRF.
Study NCT03992638 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CAF
Description: Completing root coverage by coronally advanced flap technique alone
Study NCT01955382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Actidose Aqua
Description: Actidose Aqua (oAC) (Paddock Laboratories is sold over the counter in the United States in bottles containing 25 g/120 mL (NDC # 0574-0121-04) or 50 g/240 mL (NDC # 0574-0121-08). oAC is stable at room temperature.
Study NCT01955382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate
Description: Artesunate (AS) obtained from Guilin Pharma (Shanghai), the only pharmaceutical company GMP pre-qualified by the WHO. The product artesunate for injection + 5% sodium carbonate inj + 0.9% sodium chloride inj will be delivered in vials of 30 mg and 60- mg vials, respectively, and will be dosed at 2.4 mg/kg as recommended for SM treatment by the WHO
Study NCT01955382 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artesunate
Description: Artesunate (AS) obtained from Guilin Pharma (Shanghai), the only pharmaceutical company GMP pre-qualified by the WHO. The product artesunate for injection + 5% sodium carbonate inj + 0.9% sodium chloride inj will be delivered in vials of 30 mg and 60- mg vials, respectively, and will be dosed at 2.4 mg/kg as recommended for SM treatment by the WHO
Study NCT01955382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amodiaquine
Description: Amodiaquine obtained from Pfizer (Dakar), is provided as 200-mg tablets or syrup (50 10 mg/mL), and will be provided as age-based doses per the manufacturer's directions.
Study NCT01955382 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amodiaquine
Description: Amodiaquine obtained from Pfizer (Dakar), is provided as 200-mg tablets or syrup (50 10 mg/mL), and will be provided as age-based doses per the manufacturer's directions.
Study NCT03324685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB074
Description: BIIB074 is administered as specified in the treatment arm.
Study NCT03324685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC (ethinyl estradiol and levonorgestrel)
Description: OC is administered as specified in the treatment arm.
Study NCT02705911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric handgrip exercise
Description: Participants have to perform 4 x 2 minute contractions with alternating hands, separated with 1 minute rest period using a ZonaHealth device;
Study NCT02705911 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic endurance training
Description: To perform 150 minutes extra/week at moderate aerobic intensity
Study NCT03243760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCI15106 7.5 mg capsule
Description: Orange capsule containing a white to off-white powder, 21.4 mg of CCI15106: Trehalose:Trileucine 35/55/10 weight by weight (w/w)
Study NCT03243760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Orange capsule containing a white to off-white powder, 21.4 mg of Trehalose:Trileucine 85/15 w/w
Study NCT03563560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicine
Description: 60 mg/m2/day, 30-minute IV infusion for 3 days from Day 5 to Day 7
Study NCT01535911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy restricted Ketogenic Diet (ERKD) (Metabolic Nutritional Therapy)
Description: Adult subjects with newly diagnosed glioblastoma will be referred to the study. Residual tumor size will be determined using MRI imaging. Subjects will be placed on ERKD while they are being treated with radiation therapy and standard of care chemotherapy. After completion of radiation therapy, tumor size will be determined using MRI. If the tumor has decreased in size or remained the same (stable disease), the subjects will be continued on the ERKD for an additional 6 weeks. Total calories consumed by each subject will be targeted to 20 to 25 kcal/kg/day. If the tumor has decreased in size or the size has remained the same then subjects will be continued on the ERKD for as additional 6 weeks and a repeat MRI will be obtained.
Study NCT03243760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-2
Description: Orange capsule containing a white to off-white powder, 21.4 mg of lactose. Placebo-2 to be used if unexpected safety signals are observed with the use of matching placebo.
Study NCT01419847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclopirox
Study NCT01419847 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01518257 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A
Description: A single 200U (2 mL) dose of botulinum toxin Type A injected into the intra-articular space of the study knee on Day 1.
Study NCT01518257 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: A single 2 mL dose of Normal Saline (placebo) injected into the intra-articular space of the study knee on Day 1.
Study NCT01936012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg tablets of PT Dexa Medica
Description: Each tablet contains 10.89 mg of lisinopril dihydrate that equal to 10 mg lisinopril. Test product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
Study NCT01936012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril 10 mg tablets of PT Boehringer Ingelheim Indonesia
Description: Each tablet contains 10.89 mg of lisinopril dihydrate that equal to 10 mg lisinopril. Reference product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
Study NCT01869556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin 5IU IV bolus, followed by an infusion of oxytocin 20IU/L, running at at rate of 40mIU/min for 8 hours
Study NCT01869556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ergot
Description: Ergot 0.25mg IV
Study NCT01869556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboprost
Description: Carboprost 0.25mg IM